Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Common Equity (2022 - 2025)

Gossamer Bio's Common Equity history spans 4 years, with the latest figure at -$122.8 million for Q4 2025.

  • For Q4 2025, Common Equity fell 516.25% year-over-year to -$122.8 million; the TTM value through Dec 2025 reached -$122.8 million, down 516.25%, while the annual FY2025 figure was -$122.8 million, 516.25% down from the prior year.
  • Common Equity reached -$122.8 million in Q4 2025 per GOSS's latest filing, down from -$82.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $104.6 million in Q3 2023 to a low of -$122.8 million in Q4 2025.
  • Average Common Equity over 4 years is $5.8 million, with a median of $19.4 million recorded in 2022.
  • Peak YoY movement for Common Equity: surged 419.74% in 2023, then plummeted 516.25% in 2025.
  • A 4-year view of Common Equity shows it stood at $12.1 million in 2022, then soared by 419.74% to $62.8 million in 2023, then tumbled by 53.02% to $29.5 million in 2024, then tumbled by 516.25% to -$122.8 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Common Equity are -$122.8 million (Q4 2025), -$82.3 million (Q3 2025), and -$46.1 million (Q2 2025).